Advancing RNA manufacturing worldwide

Press releases

Stay up to date with Hongene’s latest developments — from new technologies and product launches to scientific publications, industry recognition and global events. Discover how we are advancing nucleic acid manufacturing and supporting partners across oligonucleotide and mRNA development.

Reviewed by David Butler, Chief Technology Officer at Hongene. 

David has 20 years of experience in oligonucleotide therapeutics, with leadership roles at Korro Bio, Alltrna, Wave Life Sciences, and Alnylam Pharmaceuticals. He specialises in RNA drug development, LNP delivery technologies, and scalable oligonucleotide manufacturing.

Last reviewed: 17/04/2026